Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details Narrative)

v3.20.1
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 19, 2018
Amortization expense $ 198,832 $ 198,832  
Future amortization expense, year one 795,000    
Future amortization expense, year two 795,000    
Future amortization expense, thereafter $ 788,000    
CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member]      
Purchase price     $ 8,000,000
Transaction cost     1,782
Recognition of deferred tax liability     3,037,147
Intangible asset, tax basis     $ 1,782